Methods for treating APOE4/4-associated disorders
The present disclosure provides methods of treating Alzheimer's Disease (AD) and rescuing cognitive deficits associated with AD in a subject having an apoE4/4 genotype, by administering a therapeutically effective amount of the loop-diuretic bumetanide to the subject. Also disclosed are kits for performing the method, including one or more doses of a bumetanide formulation; and which may also include instructions for treating a patient having an apoE4/4 genotype by administering bumetanide, and/or instructions and reagents for testing/identifying a subject having an apoE4/4 genotype.
1 . A method of preventing or treating Alzheimer's Disease (AD) in a subject having an apoE4/4 genotype, the method comprising administering a therapeutically effective amount of bumetanide to the subject.
2 . The method of claim 1 , wherein the administering comprises administering bumetanide to the subject at a dose of 0.05 mg/kg/day or less.
3 . The method of claim 2 , wherein the administering comprises administering bumetanide to the subject at a dose of 0.02 mg/kg/day or less.
4 . The method of claim 1 , wherein the bumetanide is formulated as an oral dosage form comprising a pharmaceutically acceptable carrier, and wherein the oral dosage form is administered orally.
5 . The method of claim 4 , wherein the oral dosage form is administered once daily as a capsule, a tablet, a disintegrating tablet or lozenge, or a sachet.
6 . The method of claim 1 , wherein the bumetanide is administered intravenously or parenterally.
7 . The method of claim 1 , wherein the bumetanide is provided in a transdermal patch.
8 . The method of claim 1 , wherein the subject is a mammal.
9 . The method of claim 8 , wherein the mammal is a human.
10 . A method of preventing or treating Alzheimer's Disease in a subject having an apoE4/4 genotype, the method comprising:
a) identifying a subject as having an apoE4/4 genotype; and
b) administering a therapeutically effective amount of bumetanide to the subject.
11 . The method of claim 10 , wherein the identifying comprises performing a PCR-based DNA analytic method on a biological sample from the subject.
12 . The method of claim 11 , further comprising isolating the biological sample from the subject.
13 . The method of claim 10 , wherein the administering comprises administering bumetanide to the subject as a dose of 0.05 mg/kg/day or less.
14 . The method of claim 13 , wherein the administering comprises administering bumetanide to the subject as a dose of 0.02 mg/kg/day or less.
15 . The method of claim 10 , wherein the bumetanide is formulated as an oral dosage form comprising a pharmaceutically acceptable carrier, and wherein the oral dosage form is administered orally.
16 . The method of claim 15 , wherein the oral dosage form is administered once daily as a capsule, a tablet, a disintegrating tablet or lozenge, or a sachet.
17 . The method of claim 10 , wherein the bumetanide is administered intravenously or parenterally.
18 . The method of claim 10 , wherein the bumetanide is provided in a transdermal patch.
19 . The method of claim 10 , wherein the subject is a mammal.
20 . The method of claim 19 , wherein the mammal is a human.